The activist investment firm Trian Fund Management has recently made three key strategic recommendations to the healthcare company Solventum, urging it to cut daily operating expenses, divest non-core business assets, and prioritize capital allocation towards a share buyback program.

Trian, in an open letter to Solventum's board of directors, emphasized that the current proportion of company management expenses is excessively high and is seriously eroding profitability. The fund recommends immediately launching a comprehensive operational efficiency assessment to achieve annual cost savings of hundreds of millions of dollars through digital transformation and process optimization. At the same time, Trian pointed out that some of Solventum's business lines are insufficiently aligned with its core strategy, recommending the divestiture of these non-core assets through strategic evaluation, with proceeds used to accelerate the stock buyback plan. The fund believes that, given the current valuation level, large-scale buybacks will be the most effective way to improve earnings per share and shareholder returns. It is worth noting that Trian's founder, Nelson Peltz, has previously pushed similar reform proposals at several listed companies. This suggestion for Solventum continues his investment strategy of enhancing shareholder value through operational optimization and capital restructuring.